Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) has received a consensus recommendation of “Buy” from the six research firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $22.25.
GLMD has been the topic of several recent research reports. ValuEngine lowered Galmed Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Maxim Group set a $14.00 price target on Galmed Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, December 6th. Zacks Investment Research upgraded Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price target on the stock in a research report on Wednesday, January 10th. Finally, HC Wainwright raised their price target on Galmed Pharmaceuticals from $18.00 to $24.00 and gave the stock a “buy” rating in a research report on Monday, February 12th.
Shares of Galmed Pharmaceuticals (NASDAQ:GLMD) traded down $0.09 on Tuesday, reaching $5.92. The company’s stock had a trading volume of 27,801 shares, compared to its average volume of 52,807. Galmed Pharmaceuticals has a 52-week low of $3.61 and a 52-week high of $12.22. The company has a market cap of $85.67, a price-to-earnings ratio of -6.04 and a beta of 2.91.
Large investors have recently bought and sold shares of the company. Deutsche Bank AG acquired a new stake in Galmed Pharmaceuticals during the 4th quarter worth $246,000. Renaissance Technologies LLC acquired a new stake in Galmed Pharmaceuticals during the 4th quarter worth $345,000. J. Goldman & Co LP acquired a new stake in Galmed Pharmaceuticals during the 4th quarter worth $569,000. Sphera Funds Management LTD. acquired a new stake in Galmed Pharmaceuticals during the 4th quarter worth $2,164,000. Finally, Park West Asset Management LLC raised its stake in Galmed Pharmaceuticals by 4.4% during the 4th quarter. Park West Asset Management LLC now owns 292,847 shares of the biopharmaceutical company’s stock worth $2,679,000 after buying an additional 12,347 shares during the period. Institutional investors and hedge funds own 18.86% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Brokerages Set Galmed Pharmaceuticals Ltd (GLMD) PT at $22.25” was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/3300393/brokerages-set-galmed-pharmaceuticals-ltd-glmd-pt-at-22-25.html.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.